Skip to main content

Neurovascular Diseases

Stroke is a medical emergency and one of the leading causes of death and disability worldwide. In this context, the Neurovascular Diseases Group was established in 2001, focusing on biomedical research into both ischemic and hemorrhagic stroke from a basic and translational perspective. Our work in this research field has covered the entire disease spectrum, from prevention and treatment to recovery. In 2017, we expanded our research interests to include vascular dementia and Alzheimer’s disease, related to the β-amyloid protein. Our ultimate goal as a research team is to help answer critical questions that will improve the clinical management of stroke and dementia, conditions with significant health impacts due to their high prevalence and associated disability. We are also committed to promoting scientific education among researchers and the society, and to fostering public engagement in these areas.

Since 2001, dozens of researchers have carried out their work in this laboratory, and as a team we have leaded translational and clinical projects through both preclinical studies with experimental models, as well as cohort studies in patients. The laboratory stands out for its extensive national and international collaborations, working closely with other research groups and the biomedical industry.

Our research focuses on identifying new therapeutic targets for cerebroprotection and brain repair, discovering diagnostic, prognostic, and recovery biomarkers in both biological fluids and neuroimaging, and investigating the mechanisms of neuronal and vascular damage. We also work in regenerative medicine and nanomedicine fields, with strong expertise in preclinical models of stroke, cerebral amyloidosis, and Alzheimer’s disease. More specifically, our main research lines are:

  • Neurovascular Protection and Repair in Stroke
  • Cerebral Amyloidosis
  • Clinical and Translational Research in Dementia

Projects

Demencia mixta por Alzheimer y enfermedad cerebrovascular: un estudio clínico y experimental.

IP: Maria Pilar Delgado Martínez
Collaborators: Francesc Pujadas Navinés, Olga Maisterra Santos, Laura Castillo Ribelles, Carles Lorenzo Bosquet, Antonio Palasi Franco, Maria Belén Gutiérrez Iglesias, Jesús Pizarro Gonzálvez, Diana Liebana Gutierrez
Funding agency: Instituto de Salud Carlos III
Funding: 134310
Reference: PI19/00217
Duration: 01/01/2020 - 30/06/2024

Identificación de biomarcadores y dianas terapéuticas para la neuroreparación durante la neurorehabilitación tras el ictus.

IP: Anna Rosell Novel
Collaborators: Mª Engracia Perez Mesquida, Xavier Buxo Masip, Miguel García Gabilondo, Nicolas Garcia Rodriguez
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI19/00186
Duration: 01/01/2020 - 30/06/2024

VALIDACIÓN DIAGNÓSTICA DE UNA PULSERA INTELIGENTE PARA LA DETECCIÓN DE FIBRIL

IP: Jorge Pagola Pérez Blanca
Collaborators: Nuria Rivas Gandara, José Alvarez Sabin, Jaume Francisco Pascual
Funding agency: Instituto de Salud Carlos III
Funding: 85910
Reference: PI20/01210
Duration: 01/01/2021 - 30/06/2025

Implicaction of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy

IP: Maria Mar Hernandez Guillamon
Collaborators: Jessica Camacho Soriano, Olga Maisterra Santos, Olalla Pancorbo Rosal
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI20/00465
Duration: 01/01/2021 - 30/06/2025

Blog

News

The Neurovascular Diseases group at VHIR will use disease models to study its pathophysiological mechanisms.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.